Document:

Exhibit 10.8

 

Social Capital Hedosophia Holdings
Corp. III

317 University Ave, Suite 200

Palo Alto, CA 94301

 

[·], 2020

 

Social Capital Holdings, Inc.

317 University Ave, Suite 200

Palo Alto, CA 94301

 

Re: Administrative Services Agreement

 

Ladies and Gentlemen:

 

This Administrative Services Agreement (this
 “Agreement”) by and between Social Capital Hedosophia Holdings Corp. III (the “Company”) and Social Capital
Holdings, Inc. (the “Provider”), dated as of the date hereof, will confirm our agreement that, commencing on the date
the securities of the Company are first listed on the New York Stock Exchange (the “NYSE”) (the “Listing Date”)
and continuing until the earlier of the consummation by the Company of an initial business combination and the Company’s
liquidation (in each case as described in the Registration Statement on Form S-1 (File No. 333-[•]) filed with the Securities
and Exchange Commission) (such earlier date hereinafter referred to as the “Termination Date”), the Provider, an affiliate
of our sponsor, SCH Sponsor Corp. III, shall make available to the Company, at 317 University Ave, Suite 200, Palo Alto, CA 94301
(or any successor location or other existing office locations of the Provider or any of its affiliates), certain office space,
administrative and support services as may be reasonably requested by the Company. In exchange therefor, the Company shall pay
the Provider the sum of $10,000 per month on the Listing Date and continuing monthly thereafter until the Termination Date.

 

The Provider hereby irrevocably waives any
and all right, title, interest, causes of action and claims of any kind (each, a “Claim”) in or to, and any and all
right to seek payment of any amounts due to it out of, the trust account established for the benefit of the public shareholders
of the Company and into which substantially all of the proceeds of the Company’s initial public offering will be deposited
(the “Trust Account”), and hereby irrevocably waives any Claim it may have in the future as a result of, or arising
out of, this Agreement, which Claim would reduce, encumber or otherwise adversely affect the Trust Account or any monies or other
assets in the Trust Account, and further agrees not to seek recourse, reimbursement, payment or satisfaction of any Claim against
the Trust Account or any monies or other assets in the Trust Account for any reason whatsoever.

 

This Agreement constitutes the entire agreement
and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings, agreements, or
representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof
or the transactions contemplated hereby.

 

    

     

    

 

This Agreement may not be amended, modified
or waived as to any particular provision, except by a written instrument executed by all parties hereto.

 

No party hereto may assign either this Agreement
or any of its rights, interests, or obligations hereunder without the prior written approval of the other party. Any purported
assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest
or title to the purported assignee.

 

Any litigation between the parties (whether
grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant
to the laws of the State of New York.

 

This Agreement may be executed in one or
more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute
one and the same Agreement.

 

[Signature page follows]

 

    

     

    

 

                            Very truly yours,

 

	 	SOCIAL CAPITAL HEDOSOPHIA HOLDINGS CORP. III
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

	AGREED TO AND ACCEPTED BY:
	 
	Social Capital Holdings, Inc.
	 
	By:	          	 
	 	Name:
	 	Title:
	 

 

[Signature Page to Administrative Services
Agreement]pbyi-ex43_373.htm

Exhibit 4.3

Description of the Registrant’s Securities Registered 

Pursuant to Section 12 of the Securities Exchange Act of 1934 

Except as otherwise indicated herein or as the context otherwise requires, references in this exhibit to “we,” “us,” “our” and “our company” refer to Puma Biotechnology, Inc. The following description of our common stock and certain provisions of our second amended and restated certificate of incorporation and third amended and restated bylaws are summaries and are qualified in their entirety by reference to the full text of our second amended and restated certificate of incorporation and third amended and restated bylaws. We urge you to read those documents, each of which are incorporated by reference as exhibits to our filings with the Securities and Exchange Commission, for additional information.   

General 

Our common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended. Our second amended and restated certificate of incorporation authorizes 100,000,000 shares of common stock, all with a par value of $0.0001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. The election of directors by holders of our common stock is determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of our common stock are entitled to receive proportionately any dividends as may be declared by our board of directors.

In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Outstanding shares of our common stock are, when issued and paid for, validly issued, fully paid and nonassessable.

Delaware Anti-Takeover Statute 

We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: 

	
 
	
•
	
before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

	
 
	
•
	
upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least eighty-five percent (85%) of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentiality whether shares held subject to the plan will be tendered in a tender or exchange offer; or

	
 
	
•
	
on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-thirds percent (66 2/3%) of the outstanding voting stock that is not owned by the interested stockholder.

In general, Section 203 defines business combination to include the following: 

	
 
	
•
	
any merger or consolidation involving the corporation and the interested stockholder;

	
 
	
•
	
any sale, transfer, pledge or other disposition of ten percent (10%) or more of the assets of the corporation involving the interested stockholder;

	
 
	
•
	
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

	
 
	
•
	
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or

	
 
	
•
	
the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.

In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, fifteen percent (15%) or more of the outstanding voting stock of the corporation.pbyi-ex1017b_376.htm

Exhibit 10.17(b)

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

AMENDING AGREEMENT
Nerlynx License Agreement

THIS AGREEMENT made effective as of the 18th day of December, 2019 (the “Amending Agreement”)

By and Between

PUMA BIOTECHNOLOGY, INC., a corporation incorporated under the laws of Delaware (“Licensor”);

and:

KNIGHT THERAPEUTICS INC., a corporation incorporated under the laws of Canada (“Knight”).

(Licensor and Knight are hereinafter individually referred to as a “Party” and collectively as the “Parties”)

WHEREAS Licensor and Knight entered into a License Agreement dated January 9, 2019 (the “Original Agreement”);

WHEREAS the Parties wish to clarify certain aspects of the Original Agreement.

NOW THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

	
1.
	
The Original Agreement is amended by adding the following as Section 6.15 thereof:

	
 
	
“6.15.
	
Royalty Allocation. The Parties confirm and agree that with respect to any and all royalties paid or payable by Knight to Licensor hereunder, [***] of any such amount shall be for and in respect of the licenses as granted hereunder to the Licensor’s Patents and Know‐How and the balance of [***] shall be for and in respect to the licenses granted hereunder for the Licensor Marks, provided, however, such allocation shall in no event increase, reduce or otherwise change any of the royalty amounts payable by Knight to Licensor in the aggregate in accordance with the terms of this Agreement.”

	
2.
	
This Amending Agreement shall enure to the benefit of and be binding upon the Parties and their respective successors and legal personal representatives.

	
3.
	
This Amending Agreement may be executed by the Parties in separate counterparts each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument. The Parties agree that this Amending Agreement may be transmitted by facsimile and that the reproduction of signatures by facsimile will be treated as binding as if originals.

 

 

	
4.
	
All other terms of the Original Agreement shall remain in full force and effect unamended and are hereby ratified by the Parties hereto in all respects.

	
5.
	
This Agreement all disputes arising out of or relating to this Agreement, or the performance, enforcement, breach or termination hereof or thereof, and any remedies relating thereto, shall be construed, governed by and interpreted in accordance with the laws of New York.

IN WITNESS WHEREOF the Parties hereto have executed this Amending Agreement as of the day and year first above written.

 

	
PUMA BIOTECHNOLOGY, INC.
	
 
	
KNIGHT THERAPEUTICS INC.

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Per:
	
 
	
/s/ Maximo F. Nougues
	
 
	
Per:
	
 
	
/s/ Amal Khouri

	
Name:
	
 
	
Maximo F. Nougues
	
 
	
Name:
	
 
	
Amal Khouri

	
Title:
	
 
	
Chief Financial Officer
	
 
	
Title:
	
 
	
VP Business Development

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]